Zevra Therapeutics (ZVRA) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Zevra Therapeutics (ZVRA) is Neutral.

The composite score behind that read is +0.01, weighing +0.20 of bullish evidence against -0.28 bearish.

Zevra Therapeutics last closed at $9.99, -1.87% on the session.

Against the IVW growth benchmark the position is -2.79% over the forecast window.

The read is built from 12 underlying insights — 7 bullish and 5 bearish.

Agreement across those insights is 58%.

Zevra Therapeutics has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Zevra Therapeutics in the 80th percentile on valuation and the 88th percentile on return on equity, where 100 is best.

Zevra Therapeutics is classified under Health Care / Pharmaceuticals, with a market capitalisation of $593.25M.

StockMap tracks Zevra Therapeutics as the 62nd largest of the 128 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 54 Moderate Underperform, 53 Neutral, 15 Strong Underperform and 6 Moderate Outperform.

On that composite Zevra Therapeutics ranks 25th of 128 in the group, against a group median of -0.24.